Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2142669 | 0.93 | PDPK1 (0.72) | PDPK1KMT2AMEN1ATMPTPN1 | |
| SCHEMBL2142907 | 0.93 | PDPK1 (0.63) | PDPK1KMT2AMEN1ATMRAD52 | |
| SCHEMBL2139929 | 0.92 | KMT2A (0.59) | PDPK1KMT2AMEN1ATMNPC1 | |
| SCHEMBL2142802 | 0.92 | PDPK1 (0.55) | PDPK1KMT2AMEN1POLB | |
| SCHEMBL2140367 | 0.89 | L3MBTL1 (0.55) | PDPK1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL8876583 | 0.85 | PDPK1 (0.54) | PDPK1KMT2AMEN1ATMPOLB | |
| SCHEMBL2141782 | 0.84 | ALDH1A1 (0.57) | PDPK1KMT2APOLB | |
| SCHEMBL656058 | 0.83 | PDPK1 (0.62) | PDPK1KMT2AMEN1POLB | |
| SCHEMBL8878618 | 0.82 | PDPK1 (0.51) | PDPK1KMT2AMEN1ATMNPC1 | |
| SCHEMBL8877683 | 0.80 | PDPK1 (0.49) | PDPK1RAD52TSHRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258477-B1 | CATALYST AND MICHAEL ADDITION REACTION PROCESS | JAPAN SCIENCE & TECH AGENCY (JP) | 2015-03-25 | — | — | EP | disclosed |
| US-8222177-B2 | Catalyst and reaction process | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258477-A1 | CATALYST AND REACTION PROCESS | Japan Science and Technology Agency (JP) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009096409-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | ME1, MAL2, ME2 | PDPK1 4324/4885KMT2A 2297/4885MEN1 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.